TriSalus Life Sciences (TLSIW) Return on Equity (2021 - 2026)

TriSalus Life Sciences has reported Return on Equity for 6 years, with the latest figure at 0.03% in Q1 2026.

• For the quarter ending Q1 2026, Return on Equity rose 2.0% year-over-year to 0.03%; the trailing twelve-month figure through Mar 2026 stood at 0.03% (up 2.0% YoY), and the FY2025 full-year result was 0.01%, changed 0.0% from the prior year.
• Return on Equity for Q1 2026 stood at 0.03%, up from 0.01% in the prior quarter.
• The five-year high for Return on Equity was 0.06% in Q4 2023, with the low at 0.0% in Q2 2022.
• Historically, Return on Equity has averaged 0.01% across 5 years, with a median of 0.01% in 2025.
• Annual changes were most pronounced in 2023 — Return on Equity rose 6 bps — and 2024, when it slipped 5 bps.
• TriSalus Life Sciences' Return on Equity stood at 0.0% in 2022, then jumped by 4016 bps to 0.06% in 2023, then plunged by 79 bps to 0.01% in 2024, then retreated by 0 bps to 0.01% in 2025, then soared by 100 bps to 0.03% in 2026.
• The last three Return on Equity figures came in at 0.03% (Q1 2026), 0.01% (Q4 2025), and 0.02% (Q3 2025), per Business Quant data.